May 7, 2024
Photo Credit: Henadzi Pechan, Dreamstime
CHARENTON-LE-PONT, France — EssilorLuxottica has shared five-year data on its Stellest lenses at the Association for Research in Vision and Ophthalmology (ARVO) held this week in Seattle.
Presented for the first time, the findings strengthen the existing evidence base of the lenses in slowing down myopia progression in children. The data showed that the lenses save 1.75D of myopia over five years,*1 demonstrating conclusive evidence of their efficacy in slowing down myopia progression in children in the fifth year.
The five-year results were presented at an EssilorLuxottica-sponsored session titled “Novel approaches and models in myopia management: spectacle lenses with highly aspherical lenslets,” on May 5. Dr. Björn Drobe from EssilorLuxottica’s R&D team presented the results along with Prof. Mark Bullimore, MCOptom, PhD, FAAO, who presented his insights on predictive models for axial elongation and change in myopia progression.
On May 6, Dr. Yee Ling Wong from EssilorLuxottica’s R&D team and Prof. Mark Bullimore discussed emmetropic eye growth and spectacle lenses with highly aspherical lenslets (HAL) based on findings from a recently published paper. This was presented at a second sponsored myopia session titled “Emmetropic eye growth as benchmark for myopia management using spectacle lenses with highly aspherical lenslets.” Essilor Stellest lenses are based on the optical design of HAL lenses. Both sessions were moderated by Olga Prenat, Head of Medical and Professional Affairs at EssilorLuxottica.
“We are excited to be able to share the latest five-year findings of HAL lenses at ARVO, as long-term clinical data is essential to showcase the continued efficacy and performance of the lens in children,” said Norbert Gorny, Chief Scientific Officer at EssilorLuxottica. “As we already know that every diopter matters, we look forward to sharing scientific data and insights on interventions to address myopia, to bring us all one step closer to protecting the vision of young patients. We will also continue to integrate scientific knowledge with innovative technologies to create the future of myopia control spectacle lenses so that the next generation can see more and be more.”
“We are very happy to welcome attendees at our EssilorLuxottica booth where they can discover the company’s innovative R&D capabilities and expertise in vision care, and meet our R&D and Medical and Professional Affairs teams,” said Olga Prenat, Head of Medical and Professional Affairs at EssilorLuxottica. “The booth will also feature our Digital Infinite Refraction range consisting of Vision-R 800, Vision-S 700, and our specialized biometer, the Myopia Expert 700, designed to monitor myopia progression based on refraction and axial length for effective myopia management.”
References
*Compared to the 60-month progression of the Virtual Control Group (predicted average annual decrease in SER by 9.7%, Smotherman C, et al. IOVS 2023;64:ARVO E-Abstract 811).
1 Li X, Huang Y, Liu C, Yin Z, Cui Z, Lim EW, Drobe B, Chen H, Bao J. Myopia control efficacy of Spectacle Lenses with Highly Aspherical Lenslets: results of a 5-year follow-up study. ARVO Annual Meeting, Seattle. 2024.
